Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim result... by Sequist, Lecia V, MD, Han, Ji-Youn, Prof, Ahn, Myung-Ju, Prof, Cho, Byoung Chul, MD, Yu, Helena, MD, Kim, Sang-We, Prof, Yang, James Chih-Hsin, Prof, Lee, Jong Seok, MD, Su, Wu-Chou, MD, Kowalski, Dariusz, MD, Orlov, Sergey, PhD, Cantarini, Mireille, MD, Verheijen, Remy B, PhD, Mellemgaard, Anders, MD, Ottesen, Lone, MD, Frewer, Paul, MSc, Ou, Xiaoling, PhD, Oxnard, Geoffrey, MD

Get full text